

## Sierra Leone Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Sierra Leone			
<b>2. Grant number:</b> 17-SLE-12c-X / /			
<b>3. Date of Decision Letter:</b> 16 December 2016			
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine			
<b>6. Vaccine type:</b> Pneumococcal			
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2010 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2010-2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$21,725,173 <sup>3</sup>	US\$2,336,000	US\$24,061,173
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2010-2016	2017	
Number of Pneumococcal vaccines doses		622,100	
Annual Amounts (US\$)	US\$21,725,173 <sup>5</sup>	US\$2,336,000	

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p><b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>															
<p><b>13. Self-procurement:</b> Not applicable.</p>															
<p><b>14. Co-financing obligations:</b> Reference code: 17-SLE-12c-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2017</td> </tr> <tr> <td>Number of vaccine doses</td> <td>38,300</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$126,066</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$132,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	38,300	Number of AD syringes		Number of re-constitution syringes		Number of safety boxes		Value of vaccine doses (US\$)	US\$126,066	Total co-financing payments (US\$) (including freight)	US\$132,500
Type of supplies to be purchased with Country funds in each year	2017														
Number of vaccine doses	38,300														
Number of AD syringes															
Number of re-constitution syringes															
Number of safety boxes															
Value of vaccine doses (US\$)	US\$126,066														
Total co-financing payments (US\$) (including freight)	US\$132,500														
<p><b>15. Operational support for campaigns:</b> Not applicable</p> <table border="1"> <thead> <tr> <th></th> <th>2017</th> <th>2018</th> </tr> </thead> <tbody> <tr> <td>Grant amount (US\$)</td> <td></td> <td></td> </tr> </tbody> </table>			2017	2018	Grant amount (US\$)										
	2017	2018													
Grant amount (US\$)															
<p><b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
<p><b>17. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*: The country is requested to address the financial clarifications listed in the management letter within the requested timeframe</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>															

**18. Other conditions:** Not applicable

Signed by

*Hind H. Khatib*

**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016

## Sierra Leone Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Sierra Leone			
<b>2. Grant number:</b> 17-SLE-04c-X / /			
<b>3. Date of Decision Letter:</b> 16 December 2016			
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>6</sup>:</b> 2007 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2007 -2016	2017	Total <sup>7</sup>
Programme Budget (US\$)	16,965,597 <sup>8</sup>	357,500	17,323,097
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>9</sup>			
Type of supplies to be purchased with Gavi funds in each year	2007 -2016	2017	
Number of Pentavalent vaccines doses		298,500	
Annual Amounts (US\$)	16,965,597 <sup>10</sup>	357,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>6</sup> This is the entire duration of the Programme.

<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>8</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>9</sup> This is the amount that Gavi has approved.

<sup>10</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 17-SLE-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	60,000
Value of vaccine doses (US\$)	70,239
Total co-financing payments (US\$) (including freight)	72,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:

The country is requested to address the financial clarifications listed in the management letter within the requested timeframe

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016

## Sierra Leone Support for Rotavirus Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Sierra Leone			
<b>2. Grant number:</b> 17-SLE-13b-X / /			
<b>3. Date of Decision Letter:</b> 16 December 2016			
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule			
<b>8. Programme duration<sup>11</sup>:</b> 2014 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2014-2016	2017	Total <sup>12</sup>
Programme Budget (US\$)	US\$3,093,225 <sup>13</sup>	US\$992,500	US\$4,085,725
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>14</sup>			
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017	
Number of Rotavirus vaccines doses		441,000	
Annual Amounts (US\$)	US\$3,093,225 <sup>15</sup>	US\$992,500	

<sup>11</sup> This is the entire duration of the Programme.

<sup>12</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>13</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>14</sup> This is the amount that Gavi has approved.

<sup>15</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.															
<b>13. Self-procurement:</b> Not applicable															
<p><b>14. Co-financing obligations:</b> Reference code: 17-SLE-13b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2017</td> </tr> <tr> <td>Number of vaccine doses</td> <td>43,500</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$94,390</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$97,000</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	43,500	Number of AD syringes		Number of re-constitution syringes		Number of safety boxes		Value of vaccine doses (US\$)	US\$94,390	Total co-financing payments (US\$) (including freight)	US\$97,000
Type of supplies to be purchased with Country funds in each year	2017														
Number of vaccine doses	43,500														
Number of AD syringes															
Number of re-constitution syringes															
Number of safety boxes															
Value of vaccine doses (US\$)	US\$94,390														
Total co-financing payments (US\$) (including freight)	US\$97,000														
<b>15. Operational support for campaigns:</b> Not applicable															
<p><b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
<p><b>17. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*: The country is requested to address the financial clarifications listed in the management letter within the requested timeframe</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>															
<b>18. Other conditions:</b> Not applicable															

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016